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Abstract 
The Co and Fe K-edge extended X-ray absorption fine structure (EXAFS) spectra of the methionyl 
aminopeptidase from Escherichia coli (EcMetAP) have been recorded in the presence of 1 and 2 equiv of either 
Co(II) or Fe(II) (i.e., [Co(II)_(EcMetAP)], [Co(II)Co(II)(EcMetAP)], [Fe(II)_(EcMetAP)], and [Fe(II)Fe(II)(EcMetAP)]). 
The Fourier transformed data of both [Co(II)_(EcMetAP)] and [Co(II)Co(II)(EcMetAP)] are dominated by a peak at 
ca. 2.05 Å, which can be fit assuming 5 light atom (N,O) scatterers at 2.04 Å. Attempts to include a Co−Co 
interaction (in the 2.4−4.0 Å range) in the curve-fitting parameters were unsuccessful. Inclusion of multiple-
scattering contributions from the outer-shell atoms of a histidine−imidazole ring resulted in reasonable 
Debye−Waller factors for these contributions and a slight reduction in the goodness-of-fit value (f ‘). These data 
suggest that a dinuclear Co(II) center does not exist in EcMetAP and that the first Co atom is located in the 
histidine-ligated side of the active site. The EXAFS data obtained for [Fe(II)_(EcMetAP)] and 
[Fe(II)Fe(II)(EcMetAP)] indicate that Fe(II) binds to EcMetAP in a similar site to Co(II). Since no X-ray 
crystallographic data are available for any Fe(II)-substituted EcMetAP enzyme, these data provide the first 
glimpse at the Fe(II) active site of MetAP enzymes. In addition, the EXAFS data for [Co(II)Co(II)(EcMetAP)] 
incubated with the antiangiogenesis drug fumagillin are also presented. 
 
Methionyl aminopeptidases (MetAPs)1 represent a unique class of proteases that are capable of removing the N-
terminal methionine residues from nascent polypeptide chains (1−4). In the cytosol of eukaryotes, proteins are 
initiated with an N-terminal methionine residue; however, proteins synthesized in prokaryotes, mitochondria, 
and chloroplasts are initiated with an N-terminal formylmethionyl residue. The formyl group is initially removed 
by a peptide deformylase before MetAP's remove the N-terminal methionine (2). Removal of N-terminal 
methionine residues from nearly all newly synthesized peptides, depending on the nature of the penultimate 
amino acid, is essential for cotranslational and posttranslational modifications that are critical for fully functional 
enzymes (5), correct cellular localization, and the timely degradation of proteins (1−4). Deletion of the gene 
encoding MetAP is lethal to Escherichia coli, Salmonella typhimurium, and Saccharomyces cerevisiae; therefore, 
MetAP's are essential for cell growth and proliferation (6−8). Recently, the type II MetAP from eukaryotes has 
been identified as the molecular target for the antiangiogenesis drugs ovalicin and fumagillin (9−13). Thus, the 
inhibition of aminopeptidase activity in malignant tumors is critically important in preventing the growth and 
proliferation of these types of cells and, for this reason, has become the subject of intense efforts in inhibitor 
design. 
The MetAP's from E. coli, Homo sapiens, and Pyrococcus furiosus have been crystallographically characterized 
(13−16). These MetAP's and all other MetAP's studied to date have been shown to have identical catalytic 
domains that contain a bis(μ-carboxylato)(μ-aquo/hydroxo)dicobalt core with an additional carboxylate residue 
at each metal site and a single histidine residue bound to one of the two metal ions (13−16). Recently, it was 
suggested that the in vivo metal ion for the MetAP from E. coli (EcMetAP) is Fe(II) on the basis of a combination 
of whole cell metal analyses and activity measurements as well as in vitro activity measurements and substrate 
binding constants (17, 18). In addition, the observed catalytic activity as a function of divalent metal ion and the 
metal binding constants for both Fe(II) and Co(II) EcMetAP led to the proposal that EcMetAP functions as a 
mononuclear enzyme in vivo (17). The high-affinity or catalytically relevant metal binding site was assigned as 
the histidine-containing site; however, no structural data exist to verify these kinetic and spectroscopic data. 
Extended X-ray absorption fine structure (EXAFS) spectroscopy is particularly well suited to clarify structural 
problems of this type (19, 20). EXAFS data are sensitive to heavy atom scatterers in the second coordination 
sphere, providing direct evidence for dinuclear sites, if they exist. Reported herein are Co and Fe K-edge EXAFS 
data for the catalytically competent Co(II)- and Fe(II)-loaded EcMetAP and the catalytically inactive Co(III)- and 
Fe(III)-bound forms of EcMetAP. In addition, EXAFS data of the Co(II)-loaded form of EcMetAP bound by the 
antiangiogenesis agent fumagillin are presented. 
Materials and Methods 
Protein Expression and Purification.  
Recombinant EcMetAP was expressed and purified as previously described from a stock culture kindly provided 
by Drs. Brian W. Matthews and W. Todd Lowther (12, 18). Purified EcMetAP exhibited a single band on 
SDS−PAGE and a single symmetrical peak in matrix-assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometric analysis indicating Mr = 29 630 ± 10. Protein concentrations were estimated from the 
absorbance at 280 nm using an extinction coefficient of 16 500 M-1 cm-1 (12, 18). Apo-MetAP samples were 
exchanged into 25 mM HEPES, pH 7.5, containing 150 mM KCl (Centricon-10, Millipore Corp.). Apo-MetAP 
samples were incubated anaerobically with MCl2, where M = Co(II) or Fe(II) for 30 min as previously reported 
(18). 
Enzymatic Assay of EcMetAP. 
EcMetAP was assayed for catalytic activity with Met-Gly-Met-Met as the substrate (8 mM) using an HPLC 
method described previously (18). This method is based on the spectrophotometric quantitation of the reaction 
product Gly-Met-Met at 215 nm following separation on a C8 HPLC column (Phenomenex, Luna; 5 μm, 4.6 × 25 
cm). The kinetic parameter v (velocity) was determined at pH 7.5 by quantifying the tripeptide Gly-Met-Met at 
215 nm in triplicate. Enzyme activities are expressed as units per milligram, where 1 unit is defined as the 
amount of enzyme that releases 1 μmol of Gly-Met-Met at 30 °C in 1 min. Catalytic activities were determined 
with an error of ±10%. 
X-ray Absorption Spectroscopy.  
EXAFS samples of EcMetAP (1 mM) were frozen in polycarbonate cuvettes, 24 × 3 × 1 mm with a 0.025 mm 
Mylar window covering one 24 × 3 mm face. XAS data were collected at the Stanford Synchrotron Radiation 
Laboratory (SSRL) with the SPEAR storage ring operating in a dedicated mode at 3.0 GeV (Table 1). The edge 
regions for multiple scans obtained on the same sample were compared to ensure that the sample was not 
damaged by exposure to X-ray radiation. EXAFS analysis was performed using EXAFSPAK software 
(wwwssrl.slac.stanford.edu/exafspak.html), according to standard procedures (19). Multiple-scattering analysis 
was performed as described previously (21). Both single- and multiple-scattering paths ≤4.5 Å from either the Fe 
or Co atom were used to identify and quantify imidazole coordination due to histidine. Multiple scattering 
models, calculated using FEFF v7.02 (22), were based on either bis(N-
methylimidazole)bis(diphenylborondimethylglyoximato)iron(II) dichloromethane solvate (23) or 
hexakis(imidazole)cobalt(II) carbonate pentahydrate (24). The model was edited to only the metal atom and one 
imidazole, and the coordinates were imported into FEFF to calculate scattering amplitudes and phase shifts for 
each scattering path containing four or fewer legs. A constrained fitting process was then used with the 
following parameters:  Coordination numbers were constrained to be integer or half-integer values (the latter 
representing a ligand bound to one of the two metal ions); the distances for outer-shell atoms of imidazole rings 
were constrained to be a constant difference with the inner-shell imidazole atom distance. Only a single 
ΔE0 value was optimized. Scaling factors were determined from model compound analysis. Debye−Waller values 
for imidazole C2, N3, C4, and C5 atoms were constrained to be multiples of one another but were not tied to the 
first-shell [N1, (N,O)] Debye−Waller values. This allows non-imidazole first-shell ligands to have Debye−Waller 
values independent of the imidazole ligand values. Possible coordination numbers of histidyl imidazole ligands 
were chosen from fits that yielded chemically and physically reasonable Debye−Waller factors for the outer-shell 
atoms, since goodness-of-fit values (f ‘) were relatively insensitive to these coordination numbers. 
Table 1:  X-ray Absorption Spectroscopic Data Collection 
  Co EXAFS Fe EXAFS 
SR facility SSRL SSRL 
beamline 7-3, 9-3 7-3, 9-3 
current in storage ring, mA 50−100 50−100 
monochromator crystal Si[220] Si[220] 
detection method fluorescence fluorescence 
detector type solid-state arraya solid-state arraya 
scan length, min 24 20 
scans in average 10 10 
temperature, K 10 10 
energy standard Co foil, first inflection Fe foil, first inflection 
energy calibration, eV 7709.5 7111.3 
E0, eV 7715 7120 
preedge background     
energy range, eV 7390−7670 6789−7075 
Gaussian center, eV 6930 6403 
Gaussian width, eV 750 750 
spline background     
energy range, eV 7715−7952 (4) 7120−7354 (4) 
(polynomial order) 7952−8189 (4) 7354−7589 (4) 
  8189−8427 (4) 7589−7822 (4) 
a The 13-element Ge solid-state X-ray fluorescence detector at SSRL is provided by the NIH Biotechnology 
Research Resource. 
 
Results and Discussion 
Cobalt and iron K-edge X-ray absorption (XAS) spectra were acquired on 1 mM samples of EcMetAP with 1 or 2 
equiv of added Co(II) (i.e., [Co(II)_(EcMetAP)] and [Co(II)Co(II)(EcMetAP)], respectively) or 1 or 2 equiv of added 
Fe(II) (i.e., [Fe(II)_(EcMetAP)] and [Fe(II)Fe(II)(EcMetAP)], respectively), as well as for the fully loaded Co(III) and 
Fe(III) forms of the protein and for [Co(II)Co(II)(EcMetAP)] incubated with the inhibitor fumagillin. For fully 
loaded samples (e.g., [Co(II)Co(II)(EcMetAP)]), the EXAFS data reveal an average of both metal ion environments. 
The 1s → 3d preedge transitions for [Co(II)_(EcMetAP)] and [Co(II)Co(II)(EcMetAP)] occur at 7709 eV with a peak 
intensity of 0.118 and 0.127 eV, respectively (Figure 1a). Since 1s → 3d preedge transitions are Laporte 
forbidden in centrosymmetric environments (e.g., octahedral but not tetrahedral), the intensity of the 1s → 3d 
preedge transitions is inversely proportional to coordination number (assuming tetrahedral four-coordination). 
The intensities of the observed transitions for [Co(II)_(EcMetAP)] and [Co(II)Co(II)(EcMetAP)] are consistent with, 
on average, five- or six-coordinate Co(II) sites (25, 26). 
 
Figure 1 X-ray absorption K-edge spectra for EcMetAP:  (a) [Co(II)Co(II)(EcMetAP)] (solid) and [Co(II)_(EcMetAP)] 
(dotted); (b) [Fe(II)Fe(II)(EcMetAP)] (solid) and [Fe(II)_(EcMetAP)] (dotted). In the inset, the preedge 1s → 3d 
transition is expanded. 
 
Fourier transforms (FTs) of the EXAFS data for both [Co(II)_(EcMetAP)] and [Co(II)Co(II)(EcMetAP)] are 
dominated by a peak at ca. 2.05 Å (Figure 2). Excellent single-shell fits of EXAFS spectra for both 
[Co(II)_(EcMetAP)] and [Co(II)Co(II)(EcMetAP)] were obtained with 6 ± 1 N/O scatterers at 2.04 Å (fits 2−4 and 
8−10; Table 2). Attempts to include a Co−Co interaction (in the 2.4−4.0 Å range) in the curve-fitting parameters 
were unsuccessful. Inclusion of multiple-scattering contributions from the outer-shell atoms of a 
histidine−imidazole ring results in reasonable Debye−Waller factors for these contributions and a slight 
reduction in the goodness-of-fit value (f ‘) (fits 5 and 11; Table 2). This is consistent with the suggestion of a 
single histidine ligand from the crystallographic analyses (13−16). The Debye−Waller factor values are higher for 
[Co(II)Co(II)(EcMetAP)] than for [Co(II)_(EcMetAP)], suggesting that the first Co atom is located in the histidine-
ligated site. 
 
Figure 2 k3-weighted Co EXAFS (top) and Fourier transforms (bottom, over k = 2−12 Å-1) for 
[Co(II)Co(II)(EcMetAP)] (a; solid) and the calculated spectra for Co−(O,N)5(imid) (dotted; fit 11, Table 2) and 
[Co(II)_(EcMetAP)] (b; solid) and the calculated spectra for Co−(O,N)5(imid) (dotted; fit 5, Table 2). 
 
Table 2:  Curve-Fitting Results for Co EcMetAP EXAFSa 
  fit shell Ns Ras (Å) σas2 (Å2) ΔE0 (eV) f ‘ b 
[Co(II)_(EcMetAP)], 1 Co−O 4 2.05 0.0060 −1.17 0.094 
MC20C, 2−12 Å-1, 2 Co−O 5 2.04 0.0078 −1.28 0.084 
Δk3χ = 10.75 3 Co−O 6 2.05 0.0096 −1.43 0.082 
  4 Co−O 7 2.04 0.0114 −1.57 0.084 
  5 Co−(O,N) 6 2.05 0.0078 −1.29 0.077 
    Co−C 1 2.85 0.0041     
    Co−C 1 [2.96] [0.0043]     
    Co−C 1 [3.93] [0.0057]     
    Co−N 1 [3.99] [0.0057]     
  6 Co−O 5 2.05 0.0078 −1.25 0.083 
    Co−Co 1 3.19 0.0140     
[Co(II)Co(II)(EcMetAP)], 7 Co−O 4 2.06 0.0052 −0.74 0.090 
MC22C, 2−12 Å-1, 8 Co−O 5 2.05 0.0068 −0.84 0.078 
Δk3χ = 11.42 9 Co−O 6 2.05 0.0084 −1.03 0.072 
  10 Co−O 7 2.05 0.0103 −1.21 0.073 
  11 Co−(O,N) 6 2.05 0.0085 −0.99 0.069 
    Co−C 1 2.83 0.0063     
    Co−C 1 [2.95] [0.0066]     
    Co−C 1 [3.90] [0.0087]     
    Co−N 1 [3.97] [0.0088]     
  12 Co−O 5 2.06 0.0068 −0.83 0.077 
    Co−Co 1 3.14 0.0250     
[Co(III)Co(III)(EcMetAP)], 13 Co−O 4 2.05 0.0076 0.25 0.087 
MC33C, 2−12 Å-1, 14 Co−O 5 2.05 0.0097 0.02 0.078 
Δk3χ = 11.23 15 Co−O 6 2.04 0.0120 −0.35 0.076 
  16 Co−O 7 2.04 0.0139 −0.67 0.077 
  17 Co−(O,N) 5 2.05 0.0097 0.05 0.076 
    Co−C 1 2.85 0.0133     
    Co−C 1 [2.96] [0.0138]     
    Co−C 1 [3.92] [0.0183]     
    Co−N 1 [3.99] [0.0187]     
  18 Co−O 5 2.05 0.0097 −0.07 0.078 
    Co−Co 1 3.07 0.0299     
a Shell is the chemical unit defined for single- and multiple-scattering calculations. Ns is the number of scatterers 
per shell. Ras is the metal scatterer distance. σas2 is a mean square deviation in Ras. ΔE0 is the shift in E0 for the 
theoretical scattering functions. Numbers in square brackets were constrained to be multiples of the value 
above.b f ‘ is a normalized error (chi-squared):  f‘ = {∑i[k3(−)]2/N}1/2/[(k3)max − (k3)min]. 
 
The observed EXAFS spectra of Co(II)-loaded EcMetAP suggest that the Co(II) ions reside in a distorted penta- or 
hexacoordinate geometry, containing a histidine ligand. This is consistent with the X-ray crystal structure of 
Co(II)-loaded EcMetAP, which indicates that the histidine-ligated Co(II) ion resides in a distorted trigonal-
bipyramidal coordination environment while the second Co(II) ion is either trigonal bipyramidal or distorted 
octahedral (16, 27). The average bond distances obtained by EXAFS for both EcMetAP samples are in excellent 
agreement with the crystallographically determined bond lengths for [Co(II)Co(II)(EcMetAP)] of 2.04 Å (16). 
Additionally, it was recently reported, on the basis of 1H NMR data, that upon the addition of Co(II) to EcMetAP 
the first Co(II) bound to the lone histidine residue in the active site (17). The previously reported electronic 
absorption spectrum of EcMetAP upon the addition of 1 equiv of Co(II) under anaerobic conditions exhibited 
three resolvable d−d transitions at 580, 630, and 690 nm (ε = 60, 50, and 20 M-1 cm-1, respectively) (17). These 
data are also consistent with the first Co(II) ion residing in a pentacoordinate environment. Similarly, the 
observed EPR spectrum of [Co(II)_(EcMetAP)] was shown to be a broad, featureless signal, suggesting an 
unconstrained ligand field (17). Thus, there is a great deal of flexibility in the ligand environment (28, 29). 
Moreover, the low E/D value of 0.09 (in general, 1/3 ≥ E/D ≥ 0) reported for [Co(II)_(EcMetAP)] also indicates a 
fairly high degree of axial symmetry. The combination of the electronic absorption, EPR, and EXAFS data 
suggests that the single catalytically competent Co(II) ion in EcMetAP resides in a site that is consistent with the 
histidine-containing site reported in the X-ray crystal structure of [Co(II)Co(II)(EcMetAP)] (16). Furthermore, the 
EXAFS data do not detect a Co−Co interation, providing no support for a dinuclear Co(II) site in EcMetAP, as 
seen in the published X-ray crystal structures for all MetAP's (15, 16). 
The 1s → 3d preedge transitions are observed at 7113 eV with intensities of 0.130 and 0.151 eV for 
[Fe(II)_(EcMetAP)] and [Fe(II)Fe(II)(EcMetAP)], respectively (Figure 1B). The intensities of the 1s → 3d transitions 
are consistent with Fe(II) sites that are, on average, five-coordinate (30). These data suggest that Fe(II) binds 
to EcMetAP in a similar site to Co(II). The Fourier transforms for [Fe(II)_(EcMetAP)] and 
[Fe(II)Fe(II)(EcMetAP)] (Figure 3, bottom), similar to the Co FTs, are dominated by peaks at ca. 2.03 Å. Excellent 
single-shell fits of this peak in both [Fe(II)_(EcMetAP)] and [Fe(II)Fe(II)(EcMetAP)] were obtained with 5 or 6 N/O 
scatterers per Fe atom at 2.04 or 2.03 Å (Fits 2, 3, 7, and 8; Table 3). Attempts to include either an Fe−Fe or an 
Fe−imidazole interaction in the curve-fitting parameters resulted in fits that did not converge. 
 
Figure 3 k3-weighted Fe EXAFS (top) and Fourier transforms (bottom, over k = 2−12 Å-1) for (a) 
[Fe(II)Fe(II)(EcMetAP)] (solid) and the calculated spectra for Fe-O5 (dotted; fit 7, Table 3) and (b) 
[Fe(II)_(EcMetAP)] (solid) and the calculated spectra for Fe−O5 (dotted; fit 2, Table 3). 
 
Table 3:  Curve-Fitting Results for Fe EcMetAP EXAFSa 
  fit shell Ns Ras (Å) σas2 (Å2) ΔE0 (eV) f ‘ 
[Fe(II)_(EcMetAP)], 1 Fe−O 4 2.04 0.0080 −0.98 0.108 
MF20C, 2−12 Å-1, 2 Fe−O 5 2.03 0.0101 −1.43 0.101 
Δk3χ = 8.42 3 Fe−O 6 2.03 0.0122 −1.81 0.101 
  4 Fe−O 7 2.03 0.0144 −2.14 0.106 
[Fe(II)Fe(II)(EcMetAP)], 6 Fe−O 4 2.03 0.0074 −2.21 0.094 
MF22C, 2−12 Å-1, 7 Fe−O 5 2.03 0.0095 −2.27 0.086 
Δk3χ = 8.35 8 Fe−O 6 2.03 0.0116 −2.47 0.087 
  9 Fe−O 7 2.03 0.0137 −2.65 0.093 
[Fe(III)Fe(III)(EcMetAP)], 10 Fe−O 4 2.02 0.0071 0.08 0.083 
MF33C, 2−12 Å-1, 11 Fe−O 5 2.02 0.0091 −0.44 0.074 
Δk3χ = 11.37 12 Fe−O 6 2.01 0.0110 −0.92 0.072 
  13 Fe−O 7 2.01 0.0129 −1.33 0.074 
a See footnotes to Table 2. 
The observed Fe(II) bond distances are in agreement with X-ray crystallographic data for the Co(II)-
loaded EcMetAP (16) and are also similar to those derived from fits of Co(II)-loaded EcMetAP. Since Fe(II)-
loaded EcMetAP is colorless, air sensitive, and EPR silent, no structural information has been reported for the 
catalytically competent [Fe(II)_(EcMetAP)] enzyme. Therefore, the EXAFS data of [Fe(II)_(EcMetAP)] and 
[Fe(II)Fe(II)(EcMetAP)] provide the first structural glimpse of the Fe(II) active site of EcMetAP and reveal that the 
first Fe(II) ion likely resides in a penta- or hexacoordinate geometry made up of oxygen or nitrogen donor 
ligands. 
The lack of M−M FT peaks in the second shell of both Fe(II)- and Co(II)-loaded EcMetAP is consistent with the 
recently reported metal binding constants. The first metal binding event for Co(II)- and Fe(II)-
substituted EcMetAP exhibited Kd values of 300 and 200 ± 200 nM, respectively (17). In addition, it was shown 
that the binding of excess metal ions (<50 equiv) resulted in the loss of ∼50% of the catalytic activity. The 
second metal binding event for Co(II) EcMetAP was shown to have a Kd value of 2.5 ± 0.5 mM (17). Therefore, 
under the conditions in which these EXAFS samples used in this study were prepared (1 mM EcMetAP plus 1 or 2 
equiv of divalent metal ion), one would not expect the second metal binding site to be occupied, consistent with 
the EXAFS data. 
The lack of a second-shell metal ion scatterer is also consistent with the reported EPR signal for 
[Co(II)Co(II)(EcMetAP)]. The EPR spectra of both [Co(II)_(EcMetAP)] and [Co(II)Co(II)(EcMetAP)] are broad, 
featureless, and indistinguishable in form, suggesting an unconstrained ligand field. The observed EPR signal for 
[Co(II)_(EcMetAP)] integrated to one Co(II) ion per MetAP enzyme, and this signal doubled in intensity upon the 
addition of a second equivalent of Co(II). Moreover, the observed EPR signals followed Curie law over the 
temperature range 4−60 K at nonsaturating microwave powers (17). These data suggest that the Co(II) ions in 
[Co(II)Co(II)(EcMetAP)] exhibit no detectable spin−spin interaction, consistent with lack of a Co−Co active site. In 
support of these data, no integer spin signal could be detected in the parallel mode for EcMetAP at pH 7.5 (17). 
These data clearly indicate that no M−M interaction exists in either the mono- or dimetal Co(II) and Fe(II) EXAFS 
samples. Therefore, a dinuclear center is not formed upon addition of 1 or 2 equiv of either Co(II) or Fe(II) 
to EcMetAP at enzyme concentrations of 1 mM, which is clearly higher than in vivo MetAP concentrations. 
Similarly, the two Fe(III) ions in Fe(III)-loaded EcMetAP do not exhibit any significant spin−spin interaction on the 
basis of EPR spectroscopic studies, similar to the two Co(II) ions in Co(II)-substituted MetAP, further indicating 
that a dinuclear active site does not exist. These data are also consistent with EXAFS spectra of 
[Co(III)Co(III)(EcMetAP)] and [Fe(III)Fe(III)(EcMetAP)] which show no M−M interaction (Figure 4; Tables 2 and 3). 
 
Figure 4 k3-weighted EXAFS (top) and Fourier transforms (bottom, over k = 2−12 Å-1) for (a) 
[Co(III)Co(III)(EcMetAP)] (solid) and the calculated spectra for Co−O5 (dotted; fit 14, Table 2) and (b) 
[Fe(III)Fe(III)(EcMetAP)] and the calculated spectra for Fe−O5 (dotted; fit 11, Table 3). 
 
The range of temperatures over which the EPR signals from Co(II)-loaded EcMetAP were detectable can be 
compared with the temperature range of the detectable EPR signal from the Co(II)-loaded aminopeptidase 
from Aeromonas proteolytica ([Co(II)Co(II)(AAP)]) (28, 29). The two cobalt ions in [Co(II)Co(II)(AAP)] were shown 
to be spin-coupled, providing a spin−spin relaxation pathway that results in the spectrum of [Co(II)Co(II)(AAP)] 
obeying 1/T dependence over only a narrow temperature range (9−15 K). This electronic communication is likely 
mechanistically important for [Co(II)Co(II)(AAP)] in that a pathway for the modulation of the Lewis acidity of one 
metal ion by the other is present. Moreover, spin−spin interactions also reveal structural motifs such as μ-OH(H) 
ligands. Since the observed EPR signal of [Co(II)Co(II)(EcMetAP)] was detectable at temperatures up to 60 K and 
the signal intensity was found to be inversely proportional to the absolute temperature, following Curie law 
dependence at nonsaturating microwave powers, one can then speculate that the proposed bridging water 
molecule observed in the X-ray crystal structure of EcMetAP is incapable of mediating detectable spin−spin 
coupling, presumably because the second metal ion does not exist in the active site in EPR-analyzed samples. 
There is precedent for metallohydrolases that have crystallographically characterized dinuclear active sites to 
exhibit catalytic activity with only one metal ion bound. For instance, AAP, which has been crystallographically 
characterized, as well as the aminopeptidase from porcine kidney have long been known to be catalytically 
active with only one divalent metal ion present (31−34). For EcMetAP, the addition of up to 200 equiv of either 
Co(II) or Fe(II) resulted in a decrease in the catalytic activity, similar to the metal binding properties of the type I 
MetAP from S. cerevisiae but different from those of AAP and porcine kidney (31−35). These data suggest that 
the binding of a second metal ion to MetAP's is actually inhibitory, which would imply that the second metal ion 
does not have a catalytic role. Inhibition of catalytic activity by excess divalent metal ions has also been 
observed for other mononuclear metalloenzymes such as carboxypeptidase Taq when overexpressed in E. 
coli (36), bovine carboxypeptidase A (37, 38), and thermolysin (39). Inhibition of carboxypeptidase A was 
attributed to excess metal ion binding to an amino acid residue in the vicinity of the metallo active site that was 
involved in catalysis (37). In addition, the authors proposed that a bridging water/hydroxide, inserted between 
the two metal ions, enhanced the formation of a dinuclear site. This proposal was corroborated by X-ray 
crystallography where the structures of carboxypeptidase A, as well as thermolysin in the presence of excess 
metal ion, revealed two coordinated metal ions forming a (μ-hydroxo)dizinc(II) core with a Zn−Zn distance of 
3.48 and 3.2 Å, respectively (39−41). Therefore, the observation that the addition of excess metal ions 
to EcMetAP inhibited enzymatic activity suggests that the inhibition is likely due to the occupation of a 
noncatalytically relevant metal binding site, similar to carboxypeptidase A. 
 
Figure 5 k3-weighted Co EXAFS (top) and Fourier transforms (bottom, over k = 2−12 Å-1) for 
[Co(II)Co(II)(EcMetAP)] plus fumagillin (solid) and the calculated spectra for Co−O6 (dotted; fit 3, Table 4). 
 
An important class of MetAP inhibitors is based on natural products of fungal origin, namely, fumagillin and 
ovalicin. Ovalicin and a synthetic analogue of fumagillin (AGM-1470) have been demonstrated to preferentially 
inhibit endothelial cell growth in tumor vasculature in vivo (42). On the basis of fumagillin-specific affinity 
reagents and mass spectroscopic studies on MetAP−fumagillin complexes, MetAP's were identified as the 
specific target of fumagillins (10, 11). The mode of inhibition was shown to be via the formation of a covalent 
bond between a conserved histidine residue in MetAP's and an epoxide carbon moiety on fumagillin (10−12, 43). 
Confirmation that fumagillin reacts with the type I MetAP from E. coli comes from mass spectrometric and N-
terminal sequence analysis, which indicated that fumagillin covalently binds to an active site histidine residue 
(His79) that is not a ligand at the dinuclear active site cluster (12). To determine the interaction between the 
active site Co(II) ion of EcMetAP and the antiangiogenesis drug fumagillin, the EXAFS spectrum of 
[Co(II)Co(II)(EcMetAP)] was recorded after reaction with fumagillin. That fumagillin was covalently bound to a 
divalent metal ion loaded EcMetAP was verified by matrix-assisted laser desorption ionization time-of-flight 
(MALDI-TOF) spectrometric analysis, which revealed a mass shift of 451 Da, in excellent agreement with the 
mass of fumagillin (458 Da). 
 
Figure 6 X-ray absorption K-edge spectra for [Co(II)Co(II)(EcMetAP)] plus fumagillin. In the inset, the preedge 1s 
→ 3d transition is expanded. 
 
Interestingly, but perhaps not surprisingly, no significant change in the XAS data for [Co(II)Co(II)(EcMetAP)] in 
the presence of fumagillin was observed (Figure 5). The 1s → 3d preedge transition observed for 
[Co(II)Co(II)(EcMetAP)]−fumagillin occurs at 7709 eV with a peak intensity of 0.127 eV suggesting five- or six-
coordinate Co(II) sites (Figure 6) (25, 26). Excellent single-shell fits of the EXAFS spectrum of 
[Co(II)Co(II)(EcMetAP)]−fumagillin were obtained with 5 or 6 N/O scatterers at 2.05 Å, based on Debye−Waller 
factors. The residuals of the fits (f ‘ for fits 2 and 3; Table 4) were similar to those observed for 
[Co(II)Co(II)(EcMetAP)] without added fumagillin. Fits that include either a Co−Co interaction or the multiple-
scattering contributions from outer-shell atoms of a histidine ligand resulted in unreasonably high Debye−Waller 
factors (fits 5 and 6; Table 4). These data suggest that a dinuclear Co(II) site does not exist in 
[Co(II)Co(II)(EcMetAP)]−fumagillin, contrary to the published X-ray crystal structures for the MetAP from H. 
sapiens (13). These data strongly suggest that, upon fumagillin binding, there is little, if any, change in the 
coordination sphere of the average Co(II) site. 
Table 4:  Curve-Fitting Results for [CoCo(EcMetAP)] + Fumagillin EXAFSa 
  fit shell Ns Ras (Å) σas2 (Å2) ΔE0 (eV) f ‘ 
[Co(II)Co(II)(EcMetAP)] + fum, 1 Co−O 4 2.06 0.0048 −0.53 0.095 
MC2FA, 2−12 Å-1, 2 Co−O 5 2.05 0.0064 −0.59 0.084 
Δk3χ = 11.87 3 Co−O 6 2.05 0.0080 −0.84 0.079 
  4 Co−O 7 2.05 0.0096 −1.02 0.080 
  5 Co−(O,N) 6 2.06 0.0080 −0.76 0.077 
    Co−C 1 2.88 0.0143     
    Co−C 1 [3.00] [0.0148]     
    Co−C 1 [3.97] [0.0196]     
    Co−N 1 [4.04] [0.0200]     
  6 Co−O 6 2.06 0.0080 −0.83 0.078 
    Co−Co 1 3.04 0.0196     
a See footnotes to Table 2. 
Comparison of the EXAFS spectroscopic results for [Co(II)Co(II)(EcMetAP)]−fumagillin with the recent 1.8 Å X-ray 
crystal structure of the type II MetAP from H. sapiens complexed with fumagillin (13) reveals striking similarities 
and differences. In the X-ray structure, the epoxide-bearing side chain of fumagillin occupies the putative 
substrate binding pocket of HsMetAP. The long unsaturated side chain is analogous to the COOH-terminal 
peptide chain in the X-ray structure of a substrate analogue inhibited form of EcMetAP (15). The crystallographic 
results also verify that a covalent bond is formed between the reactive ring epoxide of fumagillin and His231 in 
the active site of the type II MetAP. The oxygen atom liberated from the breaking of the epoxide bond is 3.28 Å 
away from Co1, the Co(II) ion bound by His331, Glu364, and the two bridging carboxylate residues, Asp262 and 
Glu459. This alkoxide oxygen atom was suggested to be directly coordinated to Co. The EXAFS results presented 
herein clearly indicate that the alkoxide oxygen atom of fumagillin is not an additional ligand to the Co(II) ion 
bound in the active site of EcMetAP, contrary to the suggestion by Liu et al. (13). Closer inspection of the X-ray 
crystal structure of HsMetAP complexed by fumagillin indicates that the approximate location of the alkoxide 
oxygen of fumagillin is where a water molecule resided at >3 Å from the Co(II) ion in the uncomplexed structure. 
Therefore, we propose that the oxygen atom liberated upon the addition of fumagillin to EcMetAP displaces the 
water molecule that bridges between His178 and the water molecule bridging the two Co(II) ions in the X-ray 
structure of native EcMetAP (Figure 7). Thus, fumagillin does not provide a ligand to the metal ion in 
the EcMetAP active site. Since fumagillin has two reactive epoxide moieties, it is quite cytotoxic, probably due to 
alkylation of other biomolecules within the cell. Therefore, understanding the molecular mechanism of the 
MetAP-catalyzed cleavage of N-terminal methionine residues as well as the binding mode of known 
antiangiogenesis drugs will facilitate the rational design of new, more potent MetAP inhibitors with improved in 
vivo stability, specificity, and lower cytotoxicity. 
 
Figure 7 Proposed structure of the mono-Co(II) or mono-Fe(II) forms of EcMetAP in the presence of fumagillin. 
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